HOOKIPA Pharma Inc.

14 articles with HOOKIPA Pharma Inc.

• HOOKIPA Pharma to Participate in Upcoming Investor Conferences in June

  6/10/2021

  HOOKIPA Pharma Inc. today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences.

• HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

  6/7/2021

  Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool) .

• HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO

  5/20/2021

  Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral presentation Early dose escalation study will highlight antigen-specific CD8+ T cell data, anti-tumor activity and overall tolerability of HB-201 and HB-201/HB-202

• HOOKIPA Pharma Reports First Quarter 2021 Financial Results and Recent Highlights

  5/12/2021

  Oncology programs advance with preliminary Phase 1 immunogenicity data showing robust antigen-specific CD8+ T cell response after one dose of HB-201 or HB-202; clinical results consistent with those observed in pre-clinical studies

• HOOKIPA Pharma to Report First Quarter 2021 Financial Results on Wednesday, May 12, 2021

  5/3/2021

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release first quarter 2021 financial results before the market opens on Wednesday, May 12, 2021.

• HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

  4/29/2021

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at the following upcoming virtual investor conferences: 7th Annual Truist Securities Life Sciences Summit, May 4 – 5, 2021 Fireside Chat: May 4, 1:50pm ET

• 

  Clinical Catch-Up: April 12-16

  4/19/2021

  It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.

• HOOKIPA Pharma to Present at Kempen Life Science Conference

  4/14/2021

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021.

• HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

  4/10/2021

  Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after one dose of HB-201 or HB-202

• HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Outlook

  3/18/2021

  Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202

• HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

  3/9/2021

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2020 financial results before the market opens on Thursday, March 18, 2021. Following the release, the Company will host a live conference call and webcast at 8:30 am EDT to discuss its financial results

• Pre-clinical data on HOOKIPA’s alternating 2-vector cancer therapeutics published in Cell Reports Medicine

  3/4/2021

  Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific responses exceeding 50% of the circulating CD8 T cells 2-vector approach resulted in tumor cures and long-term immunity against tumor rechallenge Publication underscores the potential of HOOKIPA’s engineered arenavirus platform as a new class of cancer immunotherapeutics, currently being evaluated in a Phase 1/2 clinical trial in HPV16+ cancers

• HOOKIPA Pharma to Participate in Upcoming H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the upcoming H.C. Wainwright Global Life Sciences Conference held virtually from March 9-10, 2021:

• HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference

  2/16/2021

  HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that HOOKIPA’s management team will participate in the upcoming virtual SVB Leerink Global Healthcare Conference